loading page

Designing and Modelling of Trivalent Chimeric Vaccine for Capripoxvirus: Lumpy Skin Disease, Sheep Pox and Goat Pox by Immunoinformatics Approaches
  • +3
  • PASHUPATHI M,
  • Anbazhagan S,
  • Barkathullah N,
  • Swagatika Priyadarsini,
  • Snehasmita Panda,
  • Nikhil K.C
PASHUPATHI M
Indian Veterinary Research Institute

Corresponding Author:[email protected]

Author Profile
Anbazhagan S
Indian Veterinary Research Institute
Author Profile
Barkathullah N
Indian Veterinary Research Institute
Author Profile
Swagatika Priyadarsini
Indian Veterinary Research Institute
Author Profile
Snehasmita Panda
Indian Veterinary Research Institute
Author Profile
Nikhil K.C
Indian Veterinary Research Institute
Author Profile

Abstract

Capripoxvirus, a member of the poxviridae family causes three economically important diseases in ruminants namely, lumpy skin disease (LSD) in cattle, sheeppox in sheep, and goatpox in goats. Albeit non-zoonotic in nature, they have the potential to cause high economic loss among the farmers. Capripoxvirus members share common structural proteins and can rise cross-immunity among them. The present study aimed to design a recombinant chimeric vaccine from immunogenic proteins of these three members to protect all the host species by using immunoinformatics analysis and adding approved adjuvants. The palmitoylated EEV (Extracellular Enveloped Virion) membrane glycoprotein of LSD virus, SPPV-ORF 117 of sheeppox virus, B5R (EEV host range protein) of goatpox virus, and a common protein to all the members, P32, were the major immunodominant proteins used in the present chimeric vaccine construction. Several computational programs were employed to define the most immunogenic regions in selected proteins and different possible adjuvants and universal T-helper agonists were linked to the new construct. The designed vaccine construct was examined for physicochemical properties, immunogenicity and the 3D model was designed by using reliable software. Docking analysis and Molecular Dynamics simulation were carried out to determine the interaction between the designed vaccine and TLR molecules. Consequently, the lowest energy value showed the greater ability of the designed vaccine to interact with TLRs to induce an immune response. Besides appropriate physicochemical properties and acceptable stability in different host cells, the final designed vaccine is expected to have potential in stimulating both the humoral and cellular responses.